Taxus Cardium logo. (PRNewsFoto/Cardium Therapeutics)

TAXUS CARDIUM PHARMACEUTICALS GROUP INC (OTCMKTS:CRXM) registered a decrease of 7.8% in shorted shares. In November was announced CRXM’s total 13,000 shorted shares by FINRA. Previously was reported down change of 7.8% from 14,100 shares. TAXUS CARDIUM PHARMACEUTICALS GROUP INC (OTCMKTS:CRXM) has 13,200 shares average volume. It’ll cost 1 days for CRXM to recover its previous position.

The stock increased 17.09% or $0.011 during the last trading session, hitting $0.074.Currently Taxus Cardium Pharmaceuticals Group, Inc. is after 0.00% change in last November 5, 2017. CRXM has 5,175 shares volume. The stock underperformed the S&P 500 by 15.62%.

Taxus Cardium Pharmaceuticals Group, Inc. manages a portfolio of medical technologies in the United States.The firm is valued at $1.06 million. The firm engages in the development and commercialization of Generx, an angiogenic gene therapy product candidate that is in Phase III clinical trial for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease.Last it reported negative earnings. It also provides Excellagen technology platform, a FDA-approved flowable dermal matrix for advanced wound care treatment, as well as serves as a delivery platform for small molecule drugs, proteins, and biologics.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.